Healthcare

Cyclopharm Limited (ASX:CYC)

Industry Group : Health Care Equipment & Services | Industry Group Name : Health Care Equipment & Supplies

Market Price : AUD 1.670.045 (2.769%)

(as on 2021-09-28 09:55:21)

Market Cap : AUD 155.936 M

Dividend Yield (Annualized) : 0.620%

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
1.625 1.645 1.67 1.64L 1.72 H 1.545L 3.45 H
Last Trade 1.67
Change% 2.7692
52 W H/L 3.45/1.545
EBITDA -3.056 M
NPAT After Abnormal Items -6.044 M
Equity 17.116 M
ROE% -35.33%
Total Liabilities 11.159 M
Total Revenue 18.176 M
Cash and Cash Equivalents 1.874 M

Stock Information

Share price 1.67
Market Cap 155.936 M
Price/Gross Cash Flow -66.01
Dividend Yield Excluding Special 0.40%
Ending Shares 80.274 M
52-Week Range 1.545-3.45
P/E ratio 0.000
Sector P/E --
EPS -7.89
EV/EBITDA --
Net Profit Margin (%) -41.20%
Gross Cash Flows Per Share -0.04
Net Gearing 16.55%
Gross DPS (AUD) 0.01
Gross Dividend Yield (Annualized) 0.40%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.15
Sales Per Share 0.19
Book Value Per Share 0.21

Announcements

Heading Date/Time
Half Year 2021 Financial Results  23/08/2021 8:35AM
Dividend/Distribution - CYC  23/08/2021 8:35AM
Half Yearly Report and Accounts  23/08/2021 8:34AM
Initial Director's Interest Notice  10/08/2021 10:43AM
CYC Board Changes  10/08/2021 10:43AM
CYC First Half Trading Update  02/07/2021 8:20AM
Cyclopharm USFDA Update  28/06/2021 8:22AM
Ceasing to be a substantial holder from MUFG  07/06/2021 1:46PM
Ceasing to be a substantial holder from MS  04/06/2021 5:57PM
Becoming a substantial holder from MUFG  04/06/2021 3:31PM
Becoming a substantial holder from MS  04/06/2021 8:20AM
Ceasing to be a substantial holder from MUFG  03/06/2021 5:09PM
Ceasing to be a substantial holder from MS  02/06/2021 5:37PM
Becoming a substantial holder from MUFG  01/06/2021 5:05PM
Becoming a substantial holder from MS  31/05/2021 7:06PM
Ceasing to be a substantial holder from MUFG  26/05/2021 2:51PM
Ceasing to be a substantial holder from MS  25/05/2021 6:03PM
Becoming a substantial holder from MUFG  24/05/2021 6:48PM
Becoming a substantial holder from MS  21/05/2021 7:30PM
Ceasing to be a substantial holder from MUFG  20/05/2021 5:12PM
Ceasing to be a substantial holder from MS  20/05/2021 8:20AM
Becoming a substantial holder from MUFG  19/05/2021 5:04PM
Becoming a substantial holder from MS  18/05/2021 7:11PM
Ceasing to be a substantial holder from MUFG  18/05/2021 2:28PM
Ceasing to be a substantial holder from MS  18/05/2021 8:17AM
Becoming a substantial holder from MUFG  13/05/2021 4:33PM
Becoming a substantial holder from MS  13/05/2021 8:17AM
Ceasing to be a substantial holder from MUFG  11/05/2021 4:23PM
Ceasing to be a substantial holder from MS  10/05/2021 6:31PM

Similar Companies

Related Articles

About Company

Australian radiopharmaceutical company, Cyclopharm Limited (ASX: CYC) is focused on innovative solutions in nuclear medicine, targeted towards lung health. Serving the global medicine community since 1986, the company’s proprietary medical device and pharmaceutical products are made available under TechnegasTM, which is considered as the industry gold-standard in diagnostic functional lung imaging technology. Cyclopharm distributes its products in 57 countries with more than 1,500 nuclear medicine departments using TechnegasTM.

Corporate Information

company address Unit 4, 1 The Crescent, KINGSGROVE, NSW, AUSTRALIA, 2208

company phone(02) 9541 0411

company websitehttp://www.cyclopharm.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/12/2020 0% 0.010 0.40%
30/12/2019 0% 0.010 0.85%
30/12/2018 0% 0.010 0.90%
30/12/2017 0% 0.010 1.05%
30/12/2016 12% 0.010 1.15%
30/12/2015 100% 0.010 2.75%
30/12/2014 -- 0.000 0.00%
30/12/2013 -- 0.000 0.00%
30/12/2012 -- 0.000 0.00%
30/12/2011 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2022-08-22 2022
Report (Annual) 2022-03-28 2022
Report (Prelim) 2022-02-24 2022

Financials

Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/12/2016
Trading Revenue 14.523 M 14.079 M 13.404 M 13.189 M 14.386 M
Other Revenue 3.652 M 4.404 M 2.122 M 2.391 M 0
Total Revenue 18.176 M 18.482 M 15.527 M 15.579 M 14.386 M
Interest Income 4,410 25,513 103,411 79,529 47,308
Interest Expenses -207,859 -280,259 -26,129 -20,079 -17,952
Expenses -22.909 M -19.904 M -15.289 M -14.616 M -12.887 M
EBITDA -4.733 M -1.421 M 237,434 963,777 1.498 M
Depreciation and Amortization -910,291 -999,939 -510,230 -318,088 -106,392
Depreciation -773,697 -895,849 -420,115 -299,333 -86,265
Amortisation -136,594 -104,090 -90,115 -18,755 -20,127
EBIT -5.644 M -2.421 M -272,796 645,689 1.392 M
Pre Tax Profit -5.847 M -2.676 M -195,514 705,139 1.421 M
Tax Expense -199,527 -487,497 -153,864 -2.23 M -529,975
Net Profit After Tax -6.047 M -3.163 M -349,378 -1.525 M 891,368
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 2,969 250,952 313,922 0 0
Reported Net Profit After Abnormal Items -6.044 M -2.912 M -35,456 -1.525 M 891,368
Ending Shares 80.274 M 78.238 M 68.699 M 68.254 M 60.263 M
Weighted Average Shares 76.591 M 68.121 M 67.974 M 67.891 M 59.636 M
EPS After Abnormal Items (cents) -7.89 -4.28 -0.05 -2.25 1.49
Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/12/2016
Total Current Assets 15.979 M 19.611 M 15.454 M 16.829 M 11.061 M
Total Non Current Assets 12.296 M 12.918 M 8.082 M 6.548 M 5.354 M
Total Assets 28.275 M 32.528 M 23.537 M 23.377 M 16.415 M
Total Current Liabilities 5.684 M 3.48 M 5.219 M 5.211 M 3.896 M
Total Non Current Liabilities 5.475 M 5.844 M 1.302 M 916,384 57,365
Total Liabilities 11.159 M 9.324 M 6.521 M 6.128 M 3.953 M
Net Assets 17.116 M 23.204 M 17.016 M 17.249 M 12.462 M
Breakdown 30/12/2020 30/12/2019 30/12/2018 30/12/2017 30/12/2016
Net Operating Cash -8.935 M -489,340 -1.107 M -281,684 654,794
Net Invested Cash -874,191 -820,491 -1.403 M -1.537 M -2.221 M
Net Financing Cash Flows -985,961 8.091 M -352,453 5.828 M -753,994
End Cash Position 1.874 M 12.66 M 5.855 M 8.69 M 4.591 M
Beginning Cash 12.66 M 5.855 M 8.69 M 4.591 M 6.445 M
Exchange Rate Adjustments 8,982 23,942 28,184 88,696 465,973
Other Cash Adjustments 0 0 0 0 0
Ending Cash 1.874 M 12.66 M 5.855 M 8.69 M 4.591 M

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK